English 
How Acute myeloid leukaemia (AML) Clinical Landscape is transforming for IDH1 or IDH2 mutated patients? Key comments from ASH 2022
Acute myeloid leukaemia is a genetically heterogeneous hematologic malignancy in which approximately 8% and 12% of acute myeloid leukemias harbour an IDH1 or IDH2 mutation, respectively. A generally inferior outcome is seen with IDH1 mutations […]